FDA Issues Warning to Happiest Baby Over Unapproved Medical Claims for Sleepea Swaddle

The U.S. Food and Drug Administration (FDA) recently issued a warning letter to Happiest Baby, Inc., regarding the regulatory status of its “Sleepea” swaddle product. The agency asserts that the company markets the sleep sack as a medical device without obtaining the necessary FDA clearance or approval, citing concerns over the product’s intended use and potential health risks.

The FDA’s correspondence highlights that the company’s marketing materials describe the swaddle as a tool to prevent SIDS (Sudden Infant Death Syndrome) and promote infant sleep, which the agency classifies as medical claims. Because these claims suggest the product serves a therapeutic or diagnostic purpose, the FDA categorizes the swaddle as a medical device under the Federal Food, Drug, and Cosmetic Act. Consequently, the agency requires manufacturers to undergo a formal review process to demonstrate the safety and effectiveness of such products before they reach the market. The warning letter mandates that Happiest Baby address these regulatory deficiencies, noting that the company currently lacks the required premarket notification or approval to legally market the item for these specific health-related purposes.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 23, 2026

Author

GOAI